Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Enhertu Combo Snags EU Nod in 1st-Line HER2 Breast Cancer
Daiichi Sankyo said on September 1 that the European Commission has approved its antibody drug conjugate Enhertu (trastuzumab deruxtecan) in combination with pertuzumab as a first-line treatment for HER2-positive breast cancer. The approval covers adult patients with HER2-positive (IHC3+ or…
To read the full story
Related Article
- Enhertu Combo Scores China Nod in 1st-Line HER2 Breast Cancer
August 18, 2026
- Enhertu Combo Bags EU Panel Nod in 1st-Line HER2 Breast Cancer
July 28, 2026
- Enhertu Combo Accepted for EU Review in First-Line HER2 Breast Cancer
January 20, 2026
- Enhertu Combo Wins US FDA Nod in 1st-Line HER2 Breast Cancer
December 17, 2025
- Enhertu Combo Filed for First-Line HER2 Breast Cancer in Japan
October 8, 2025
- Enhertu Combo Accepted for US Review in First-Line HER2 Breast Cancer
September 25, 2025
- Enhertu Combo Gets Breakthrough Tag for First-Line HER2 Breast Cancer
July 22, 2025
- Enhertu Hits Mark in 1st Line Breast Cancer with PIII Trial Win
April 22, 2025
BUSINESS
- Veloxis Starts US PII Study of Novel Immunosuppressant
September 2, 2026
- Canada Backs Public Reimbursement of Leqembi
September 2, 2026
- Marubeni Pharma Sets Up Hong Kong Subsidiary
September 2, 2026
- Enhertu Combo Snags EU Nod in 1st-Line HER2 Breast Cancer
September 2, 2026
- Shionogi Pivoting to Function-Based Model in Global HR Revamp
September 1, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…